Kornimate/medical-research-clean huggingface dataset:
a study of rg1662 in individuals with down syndrome

Conditions: Down Syndrome

Summary: this multi-center, randomized double-blind, placebo-controlled study will assess the safety and tolerability of rg1662 in individuals with down syndrome. eligible subjects will be randomized in cohorts to receive either multiple oral doses of rg1662 or placebo. anticipated time on study treatment is 38 days.


Eligibility criteria:
inclusion criteria: * adult individuals, 18 to 30 years of age, with diagnosis of down syndrome (confirmed by karyotype) * males and non-pregnant non-lactating females * parent or legal guardian/representative and caregiver willing to give written informed consent * subject willing and assenting or consenting to participate exclusion criteria: * major depressive disorder not adequately controlled by a selective serotonin reuptake inhibitor or a serotonin norepinephrine reuptake inhibitor * subjects meeting clinical diagnostic criteria for autistic spectrum disorder, attention deficit or hyperactivity disorder unlikely to cooperate and take part successfully in the study assessments * subjects with other primary psychiatric diagnosis * subjects with evidence or meeting clinical diagnosis of dementia * subjects with personal history of cardiac abnormalities; patients that have previously undergone congenital heart surgery can be enrolled provided they have no residual complication requiring intervention (e.g. pace maker) * subjects with clinically significant obstructive pulmonary disease or asthma that is not adequately treated (oral steroids are not allowed) * subjects with thyroid dysfunction that is not adequately controlled and stabilized on treatment for at least 8 weeks * subjects with sustained elevated supine blood pressure (sbp/dbp) at rest exceeding 140/90 mmhg or notable resting tachycardia (mean hr \> 60 bpm) or blood pressure below 90/40 mmhg * subjects who have taken any other investigational medications within 3 months * body mass index (bmi) \> 40 kg/m2
helicobacter pylori infection in acute myocardial infarction patients

Conditions: Acute Coronary Syndrome

Summary: this study aims to investigate the association between h.pylori and acs .

the study is based on show the relationship between h.pylori infection and acute coronary syndrome . active h.pylori infection is common in acs and may represent a modifiable risk factor for upper gastrointestinal bleeding.

Eligibility criteria:
inclusion criteria: * all patients presenting by acute coronary syndrome to coronary care units, internal medicine department, sohag faculty of medicine from 18 . exclusion criteria: * 1.patients with cardiogenic shock. 2. renal impairment.(creatinine clearence \<60) 3. a known systemic inflammatory condition. 4.they had taken any antibiotics in the previous 1 months. 5.they had taken any proton pump inhibitors in previous 2 weeks. 6.gastrointestinal bleeding.
optima bi-ventricular capture verification study

Conditions: Heart Failure

Summary: the purpose of this study is to characterize the morphology (shape) of the intracardiac electrograms(egm) from patients with a resynchronization therapy device.

morphology of egm during loss of capture in either right ventricle (rv) or left ventricle (lv) at different av delays and lv offsets and during exercise. these egm signals will be used to design and develop improved automatic threshold and automatic capture algorithms for crt defibrillators (crt-d). as well, the data collected from the study will be used to to develop other automatic algorithms for crt-d, such as pacing parameter optimization.

Eligibility criteria:
inclusion criteria: * signed informed consent indicating a willingness to participate, have indications for and have been implanted with a guidant renewal 4 crt-d device exclusion criteria: * patients in atrial fibrillation that cannot be cardioverted for the study, sustained uncontrolled ventricular tachycardia (vt), sinus rhythm \ 100 bpm, complete av node block, av node ablation, severe aortic valve stenosis (valve area \< 1.0 cm squared), frequent ectopic beats that would preclude adequate testing, lead in the great cardiac vein, women who are pregnant or who plan to become pregnant.
behavioral health services for women receiving public assistance

Conditions: Mental Disorders

Summary: the purpose of this study is to determine whether access to behavioral health services has been affected by welfare reform.

this study examines patterns of behavioral health service use among a group of female household heads who receive temporary assistance to needy families (tanf) and have serious mental illness (smi). the findings from this study will be used to determine the feasibility of conducting a full-scale longitudinal study of the impact of welfare reform outcomes on female household heads who have smi and are currently or formerly recipients of welfare.

Eligibility criteria:
inclusion criteria: * female head of household on tanf at any time during first quarter of 1997 and used at least one behavioral health service during that quarter * dsm iv diagnosis of serious mental illness

Keywords: social welfare mentally ill persons mental health services
safety and efficacy evaluation of ultheratm in treatment of baggy eyelid

Conditions: Orbital Fat Prolapse

Summary: study title * safety and efficacy evaluation of ultheratm in treatment of baggy eyelid study design * single arm and investigator initiative pilot study


Eligibility criteria:
inclusion criteria: * age \>20 years, age \< 50 years * people who want to improve baggy eyelid * information consent obtained exclusion criteria: * previous lower eyelid surgical history * scar on lower eyelid after trauma * bleeding tendency * aesthetic addiction, drug abuse, alcohol abuse

Keywords: orbital computed tomography baggy eyelids orbital fat prolapse ultheratm high intensity focused ultrasound
can plia reduce early post-operative pain after pao surgery?

Conditions: Hip Dysplasia

Summary: the goal of this clinical trial is to compare different peri-incisional local infiltrative anesthesia (plia) methods in patients ages 13 to 50 undergoing a periacetabular osteotomy (pao). the main questions to answer here are: 1. does plia impact post-operative pain after pao? 2. does plia impact pain medication usage as measured by morphine equivalent dosing (med) after pao? 3. does the timing of plia administration impact post-operative pain and med after pao? participants will be asked to complete some surveys; demographics survey, general self-efficacy scale (gse) and the pain resilience scale. all other information will be gathered from the patients medical chart. researchers will compare three groups. 1.) patients who do not receive plia. 2.) patients who receive plia after their incision is closed. 3.) patients who receive plia throughout pao.

patients will be approached at their preoperative appointment. this is the only time researchers will conduct study related activities with patients. all other information will be gathered by chart review. following consent, patients will be asked to complete surveys through redcap® using a tablet or computer. these include a self-efficacy survey and a grit survey. patients will then be randomized in a 1:1:1 ratio. 1.) patients who do not receive plia. 2.) patients who receive plia after their incision is closed. 3.) patients who receive plia throughout pao. patients will be blinded to which group they are in, meaning they will not know whether they received the injection or not. patients may ask to be told what study group they were in at their standard-of-care, 3 month follow-up visit. following surgery, patients in all treatment arms will be provided with the same intravenous (patient-controlled analgesia) and oral pain medications scheduled as needed per standard of care. the research team will review patient medical records to record narcotic use and visual analog scale (vas) pain scores post-operatively until discharge from the hospital.

Eligibility criteria:
inclusion criteria: * adolescent or young adult diagnosed with hip dysplasia indicated for pao at university of iowa hospital and clinics. exclusion criteria: * unable to provide informed consent. * pregnant or breast-feeding individuals * prisoner or ward of the state * allergy or medical contradiction to any of the study medications * patients undergoing femoral osteotomy or surgical hip dislocation with pao will be excluded

Keywords: hip dysplasia periacetabular osteotomy plia peri-incisional local infiltrative anesthesia
effects of semg biofeedback with core muscle strengthening exercises and kinesiotaping on diastasis recti in post-partum women

Conditions: Diastasis Recti Abdominis

Summary: diastasis rectus abdominis is quite common during and after pregnancy. abdominal core strengthening exercises have been proven to be very effective in reducing inter rectus distance, however, the role of biofeedback emg assisted exercises in diastasis rectus have been poorly understood.

this study is a randomized control trial in which posr-partum females with diastasis recti will be recruited into a control and two experimental groups. in control group, patients will receive standard conservative treatment, whereas, in first experimental group, participants will receive core strengthening exercises with kinesiotaping; and in second experimental group, core strengthening exercises with kinesiotaping will be assisted by semg biofeedback. patients will be evaluated pre and post-treatment for inter rectus distance, abdominal strength and quality of life.

Eligibility criteria:
inclusion criteria: * post-partum women aged 18-40 years * post-partum females from 6 to 24 months * diastasis rectus abdominus distance more than 2cm at any of 3 levels * primiparous or multiparous * spontaneous vaginal delivery and lscs exclusion criteria: * having skin sensitivity to taping * open abdominal wounds * abdominal skin diseases * abdominal hernia * other abdominal or back surgical history * any heart or respiratory conditions * neurological diseases
individual patient compassionate use of gx-i7

Conditions: Glioblastoma; High Grade Glioma; Recurrent Glioblastoma; Melanoma; Advanced Cancer

Summary: compassionate use of gx-i7 for patients with serious life-threatening illness that have exhausted all available therapies, with no other therapy options.

this program is being offered on a patient by patient basis and will require company, institutional review board/independent ethics committee and single patient ind approval.

Eligibility criteria:
inclusion criteria: - exclusion criteria: -
effects of smoking on clinical and microbiological response in individuals with periodontitis

Conditions: Periodontitis; Smoking Habit; Subgingival Plaque

Summary: this study aimed to compare the distribution of subgingival periodontal pathogens following non-surgical periodontal therapy in smoking and non-smoking people with periodontitis. the main question it aims to answer is: - does smoking affect the results of non-surgical periodontal treatment on subgingival flora in participants with periodontal disease? researchers performed non-surgical periodontal therapy on 48 participants with stage iii/iv periodontitis and recorded clinical measurements. they obtained subgingival plaque samples from periodontal pockets at the onset and after four weeks of treatment, determining the level of periodontopathogens using a polymerase chain reaction-based method.

the present study aims to compare the changes in clinical parameters and subgingival periodontopathogen rates (p. gingivalis, a. actinomycetemcomitans, t. forsythia, f. nucleatum, p. intermedia, t. denticola, p. micra, c. rectus, e. nodatum, capnocytophaga spp, and e. corrodens) following full-mouth scaling and root planing procedures in participants with and without smoking habits.

Eligibility criteria:
inclusion criteria: * having 15 or more permanent teeth (except third molars and teeth with endodontic lesions), * having been diagnosed with generalized stage iii or iv periodontitis that progresses with periodontal support tissue loss in more than 30% of the teeth, * having at least five teeth with probing depth(pd) ≥6mm, clinical attachment level(cal) ≥5mm, and radiographic bone loss that extends to at least the middle of the root, * having at least one tooth that meets the same pd and cal criteria per quadrant. exclusion criteria: * pregnancy or lactation, * any systemic disease with a potential influence on the immune response (diabetes mellitus, bone metabolic diseases, immunosuppressive therapy, radiation etc.), * existence of decay, restoration, or prosthesis on the sampling site, * use of the anti-inflammatory drug and antibiotic within the last 3 months.
the use of amh for the discrimination of polycystic and multicystic ovaries in nonhyperandrogenic patients

Conditions: Polycystic Ovary Syndrome

Summary: amh is a member of the transforming growth factor family. it is produced by the granulosa cells from 36th weeks of pregnancy.ovarian granulosa cells are the only source of the antimüllerian hormone. amh production continues until response to exogenous fsh occurs and follicles reach 4-6 mm in diameter.the number of follicles in patients with polycystic ovaries are 2-6 times higher than normal women. serum amh levels are 2-3 times higher in patients with pcos. the cause of elevated serum amh levels in patients with pcos is unknown. there are data showing elevated serum amh level is due to the increase in the number of follicles 2-8 mm in diameter. although there is no precise definition; multicystic ovarian is defined by the presence of more than six follicles 4-9 mm in diameter and mixed morphologically with pco. pco and multicystic ovaries are distinguished by the absence of the increase in stroma / volume.the aim of this study is to investigate whether there is a difference of serum amh levels between patients with pco or multicystic ovaries. a primary goal is to investigate the usability of amh as a marker besides ultrasound for discrimination of nonhyperandrogenic patients with pco or multicystic ovaries.

it is planned to compare the values of fsh/lh, amh, and 75 gr ogtt between 20 patients diagnosed as pcos according to the aes-rotterdam criteria and 20 patients with multicystic ovarian structure but do not provide the pcos-d3 criteria. the second purpose of this study is to investigate the mechanism that leads to the elevation of amh in patients with pcos, and to reveal the effects of intraovarian paracrine factors,insulin resistance and fsh /lh.

Eligibility criteria:
inclusion criteria: * between the ages of 15-43 * \>6 4-9 mm follicles in bilateral ovaries at ultrasonographic examination * increased ovarian volume (\>10 ml ) exclusion criteria: * hormonal drug users * late onset congenital adrenal hyperplasia,androgen secreted ovarian or adrenal tumors

Keywords: antimullarian hormone(amh) polycystic ovary multicystic ovary
a randomized comparison of amnioclear™ human allograft amniotic membrane vs. moist wound dressing in the treatment of diabetic wounds

Conditions: Diabetic Foot Ulcers; Wound Care

Summary: this research project is testing a product called amnioclear™ which is an amniotic membrane graft processed for liventa bioscience formerly afcell medical. amnioclear™ allograft human amniotic membrane is regulated solely under section 361 of the public health service act. the purpose of the study is to see if this treatment works to accelerate the healing time of chronic wounds.


Eligibility criteria:
inclusion criteria: * stable type i or ii diabetes mellitus * at least one chronic diabetic ulcer * full-thickness ulcer size from 1-8 cm2. exclusion criteria: * concurrent use of corticosteroids, nsaids immuno-suppressive or cytotoxic agents * bleeding disorders * ulcer with muscle, tendon, capsule or bone involvement
bendamustine and bortezomib combination therapy in indolent non-hodgkin's lymphoma(nhl)

Conditions: Lymphoma, Non-Hodgkin

Summary: the purpose of this study is to determine whether the combination of bendamustine and bortezomib in patients with indolent non-hodgkin's lymphoma or chronic lymphocytic leukemia is safe and tolerable.

bendamustin and bortezomib have been shown to be effective in the treatment of patients with indolent non-hodgkin's lymphoma (nhl) and chronic lymphocytic leukemia (cll). both compounds appear not to be cross-resistant with prior therapy. therefore, it is of interest to combine bendamustine and bortezomib in this patient population. preliminary results from patients with multiple myeloma showed that the combination of bendamustine and bortezomib is efficacious and well tolerated. however, there are so far no data on this combination in patients with nhl or cll.

Eligibility criteria:
inclusion criteria: * symptomatic recurrent or refractory indolent nhl or b-cll * adequate organ and bone marrow function * karnofsky greater than 50% exclusion criteria: * candidates for autologous stem cell transplantation * secondary high grade lymphoma * concurrent severe medical condition

Keywords: lymphoma, non-hodgkin, low-grade
efficacy and safety of vonorasan versus esomeprazole in the treatment of ulcers after endoscopic submucosal dissection

Conditions: Ulcers, Gastric

Summary: the purpose of this clinical trial is to find out the effectiveness of voronasan in combination with aluminum phosphate gel in the treatment of post-operative esd ulcers. it will also find out about the safety of vunorasan in combination with aluminum phosphate gel. the main questions it aims to answer are: 1. do vonorasan in combination with aluminum phosphate gel clinically effective in the treatment of post-operative esd ulcers? 2. what medical problems do participants have when taking drug vonorasan in combination with aluminum phosphate gel? researchers compared the drug voransen in combination with aluminum phosphate gel to esomeprazole in combination with aluminum phosphate gel to see if voransen in combination with aluminum phosphate gel worked better for post-operative esd ulcers. participants will: intravenous lansoprazole 1-3 days after esd and oral voronasan combined with aluminum phosphate gel or esomeprazole combined with aluminum phosphate gel 3-56 days after esd. record their symptoms, endoscopic ulcer grading, ulcer size and calculate ulcer healing rate at weeks 2 and 8.


Eligibility criteria:
inclusion criteria: * meets surgical indications for esd * age 18-70 years, regardless of gender * normal coagulation * esd postoperative ulcers ≤3cm * voluntary participation in the study exclusion criteria: * patients with severe complications or failure to achieve curative resection after gastric esd surgery need supplementary surgery * women who are pregnant or breastfeeding, or who may conceive during clinical trials * the patient has other serious organic diseases that affect the evaluation of the study, such as severe liver disease, heart disease, renal disease, malignant neoplasm and alcoholism * patients who need to take antiplatelet and nsaids drugs for a long period of time * co-administration of unspecified anti-ulcer drugs during the trial period;allergic reactions to vornoxan, aluminium phosphate gel or esomeprazole * patients with no capacity for autonomous behaviors, unable to correctly express their main complaint, such as those with mental illness, severe neurosis, and unable to cooperate with this experiment * esd postoperative ulcers \>3cm
acupuncture intervention to improve neurological function and anti-inflammatory effect in acute ischemic stroke (anais)

Conditions: Acute Ischemic Stroke; Acupuncture

Summary: this study will have acupuncture intervention in acute ischemic stroke patients and evaluate the effect in neurological function improving by national institutes of health stroke scale (nihss), modified rankin scale (mrs), barthel index, and antiinflammatory actions by biomarkers.

acupuncture treatment in stroke is a widely practiced in taiwan, mainland china, and around the world. the using in stroke group is countless. numerous clinical trials have been conducted in the medical community to assess efficacy, and the results mostly suggest that acupuncture may be an effective, low side effects adjuvant therapy. ischemic stroke is also associated with chronic inflammation-related diseases. in recent years, the anti-inflammatory effect of acupuncture was gradually found. so, whether in the basic or in clinical, the investigators can deduce that acupuncture may be helpful for stroke as an adjuvant therapy. this study evaluates the neurological function of patients with acute stroke by using the widely used national institutes of health stroke scale (nihss), modified rankin scale (mrs) and barthel index. also, the investigators assess the degree of inflammation by biomarkers. therefore, the purpose of this study is to explore the effect of acupuncture intervention on acute ischemic patients and its relationship in anti-inflammatory actions.

Eligibility criteria:
inclusion criteria: * clinically diagnosed acute ischemic stroke * initial nihss between 4\~20 * aged 45 \~ 85 exclusion criteria: * hemorrhagic transformation after cerebral infarction, the hemorrhage size estimated to be ≥ 2cm in diameter by brain imaging. * any intracranial hemorrhage , except hemorrhagic transformation after cerebral infarction * any intracranial operation during acute stage * patient using anticoagulants * cerebellar infarction * special causes of stroke, such as coagulation abnormalities, or arteriovenous malformations * epileptic seizures after stroke * combined with infection diseases at the time of assessment * pregnant or breastfeeding women * present mental illness or symptoms and cannot cooperate with the study * cannot sign the inform consent

Keywords: stroke acupuncture antiinflammatory nihss
the efficacy and safety of platelet-rich fibrin and platelet rich plasma in female pattern hair loss patients

Conditions: Female Pattern Hair Loss; Platelet-Rich Plasma; Platelet-rich Fibrin

Summary: the goal of this clinical trial is to compare between platelet-rich fibrin and platelet-rich plasma in female pattern hair loss . the main question\[s\] it aims to answer are: * efficacy between platelet-rich fibrin and platelet-rich plasma * safety between platelet-rich fibrin and platelet-rich plasma participants will be divided into 2 side of treatment with composed of 1. platelet rich plasma 2. platelet rich fibrin

subject was treated both platelet-rich fibrin and platelet-rich plasma for 3 times which 1 month interval then will be followed up at 4 months and 6 months after last treatment

Eligibility criteria:
inclusion criteria: * age 20-55 years * female * subject who was diagnosed with female pattern hair loss in ludwig classification 2 (part width 2-4 centimeters) by dermatologist exclusion criteria: * pregnancy or lactation subjects * subject with history of platelet dysfunction, low platelet, anemia, cirrhosis, cancer, or immunocompromised host * subject who are active smoking and alcoholism * subject who has dermatitis, scar or infection at intervention area * subject who has history of allergy to anesthesia drug * subject who taking nsaids, hormonal drug, anticoagulants drug * subject who has psychiatric condition diagnosed by psychiatrist * subject who are not allowed to take a photo

Keywords: female pattern hair loss platelet-rich plasma platelet-rich fibrin